Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 23.
doi: 10.1007/s00210-024-03542-5. Online ahead of print.

Navigating the therapeutic landscape for breast cancer: targeting breast cancer stem cells

Soudeep Dey  1 , Yirivinti Hayagreeva Dinakar  2 , Soundarya R  2 , Vikas Jain  3 , Rupshee Jain  4
Affiliations
Review

Navigating the therapeutic landscape for breast cancer: targeting breast cancer stem cells

Soudeep Dey et al. Naunyn Schmiedebergs Arch Pharmacol. .

Abstract

Breast cancer is a common and deadly malignancy that affects women globally, and breast cancer stem cells (BCSCs) play an important role in tumorigenesis, development, metastasis, and recurrence. Traditional therapies often fail to eliminate BCSCs, leading to treatment resistance and relapse. This review explores the therapeutic strategies which are designed to target BCSCs, including inhibition of key signaling pathway and targeting receptor. This paper also explores the approaches to targeting BCSCs including chemotherapy, phytomedicines, and nanotechnology. Nanotechnology has gained a lot of importance in cancer therapy because of its ability to deliver therapeutic agents with more precision and minimal side effects. Various chemotherapeutic drugs, siRNAs, or gene editing tools are delivered efficiently with the use of nanocarriers which target pathways, receptors, and proteins associated with BCSCs. Over the past few years, stimuli-responsive and receptor-targeted nanocarriers have been explored for better therapeutic effects. In recent times, strategies such as chimeric antigen receptor (CAR) T-cell therapy, ablation therapy, and cell-free therapies are explored for targeting these stem cells. This review provides a recent developmental overview of strategies to attack BCSCs from conventional chemotherapeutic agents to nanotechnological platforms such as polymeric, lipidic, and metal-based nanoparticles and advanced technologies like CAR T cell therapies.

Keywords: Breast cancer stem cells; CAR T-cell therapy; Nanotechnology; Phytomedicines; Self-renewal; Targeted therapy.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Abed A, Derakhshan M, Karimi M et al (2022) Platinum nanoparticles in biomedicine: preparation, anti-cancer activity, and drug delivery vehicles. Front Pharmacol 13:1–23. https://doi.org/10.3389/fphar.2022.797804 - DOI
    1. Adylova A, Mukhanbetzhanovna AA, Attar R et al (2021) Regulation of TGFβ/SMAD signaling by long non-coding RNAs in different cancers: dark knight in the castle of molecular oncology. Noncoding RNA Res 6:23–28. https://doi.org/10.1016/j.ncrna.2020.12.003 - DOI - PubMed - PMC
    1. Ajith AK, Subramani S, Manickam AH, Ramasamy S (2021) Chemotherapeutic resistance genes of breast cancer patients – an overview. Adv Pharm Bull 12:649–657. https://doi.org/10.34172/apb.2022.048 - DOI - PubMed - PMC
    1. Aramini B, Masciale V, Grisendi G et al (2022) Dissecting tumor growth: the role of cancer stem cells in drug resistance and recurrence. Cancers (Basel) 14:976. https://doi.org/10.3390/cancers14040976 - DOI - PubMed
    1. Asgharian P, Tazekand AP, Hosseini K et al (2022) Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets. Cancer Cell Int 22:257. https://doi.org/10.1186/s12935-022-02677-w - DOI - PubMed - PMC

LinkOut - more resources